Sethi Bipin Kumar, Baruah Manash P, Kumar A Sreenivas
Consultant Endocrinologist, CARE Hospitals, Hyderabad, Telangana.
Director and Consultant Endocrinologist, Excel Centre, Guwahati, Assam.
J Assoc Physicians India. 2017 Mar;65(3):67-71.
Recently, blood pressure variability (BPV) has gained focus owing to its role in predicting cardiovascular (CV) outcomes. Additionally, alterations in BPV contribute to the progression of end organ damage and trigger vascular events in hypertensive patients. Therefore, amelioration of BPV is considered a potentially important target and different classes of drugs are used to achieve the desired blood pressure (BP) goal. Based on several studies and clinical trials, treatments with CCB such as amlodipine have been found to be most effective in the management of BPV in hypertensive patients with diabetes. Growing evidence substantiates the role of amlodipine in significant reduction of BPV, thus, lowering the risk of diabetes related complications. This review sheds light on the importance of BPV reduction and the effectiveness of amlodipine in preventing cardiovascular morbidity and mortality in hypertensive patients with diabetes.
近年来,血压变异性(BPV)因其在预测心血管(CV)结局中的作用而受到关注。此外,BPV的改变会促使终末器官损害进展,并引发高血压患者的血管事件。因此,改善BPV被认为是一个潜在的重要靶点,不同种类的药物被用于实现理想的血压(BP)目标。基于多项研究和临床试验,已发现使用氨氯地平等CCB类药物治疗在管理糖尿病高血压患者的BPV方面最为有效。越来越多的证据证实了氨氯地平在显著降低BPV方面的作用,从而降低了糖尿病相关并发症的风险。本综述阐明了降低BPV的重要性以及氨氯地平在预防糖尿病高血压患者心血管发病和死亡方面的有效性。